建发致新：公司持续推进血管介入、外科产品及IVD诊断产品等分销与直销业务的稳定发展

证券之星06-04

证券之星消息，建发致新(301584)06月03日在投资者关系平台上答复投资者关心的问题。

投资者提问：董秘您好：作为贵公司的投资者，请问贵公司的神经血管介入市场在国内外的市场份额是多少？？谢谢！！

建发致新回复：尊敬的投资者，您好！公司具体经营数据敬请关注公司在指定信息披露媒体披露的定期报告。公司持续推进血管介入、外科产品及IVD诊断产品等分销与直销业务的稳定发展，致力于巩固并提升市场份额。感谢您的关注！

本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2640133385?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-04 09:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640133385","market":"hk","top_or_hot":-1,"title":"建发致新：公司持续推进血管介入、外科产品及IVD诊断产品等分销与直销业务的稳定发展","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/301584\">建发致新</a>(301584)06月03日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：董秘您好：作为贵公司的投资者，请问贵公司的神经血管介入市场在国内外的市场份额是多少？？谢谢！！</p><p>建发致新回复：尊敬的投资者，您好！公司具体经营数据敬请关注公司在指定信息披露媒体披露的定期报告。公司持续推进血管介入、外科产品及IVD诊断产品等分销与直销业务的稳定发展，致力于巩固并提升市场份额。感谢您的关注！</p><p>本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>建发致新：公司持续推进血管介入、外科产品及IVD诊断产品等分销与直销业务的稳定发展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n建发致新：公司持续推进血管介入、外科产品及IVD诊断产品等分销与直销业务的稳定发展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-04 09:01 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026060400005060.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，建发致新(301584)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好：作为贵公司的投资者，请问贵公司的神经血管介入市场在国内外的市场份额是多少？？谢谢！！建发致新回复：尊敬的投资者，您好！公司具体经营数据敬请关注公司在指定信息披露媒体披露的定期报告。公司持续推进血管介入、外科产品及IVD诊断产品等分销与直销业务的稳定发展，致力于巩固并提升市场份额。感谢您的...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026060400005060.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"301584","symbol_name":"建发致新","start_time":0,"source_url":"https://stock.stockstar.com/RB2026060400005060.shtml","article_id":"2640133385","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640133385","pubTimestamp":1780534883,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，建发致新(301584)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好：作为贵公司的投资者，请问贵公司的神经血管介入市场在国内外的市场份额是多少？？谢谢！！建发致新回复：尊敬的投资者，您好！公司具体经营数据敬请关注公司在指定信息披露媒体披露的定期报告。公司持续推进血管介入、外科产品及IVD诊断产品等分销与直销业务的稳定发展，致力于巩固并提升市场份额。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"301584":"建发致新","BK0250":"批发"},"translate_title":"C&D Zhixin: The Company continues to promote the stable development of distribution and direct sales of vascular interventions, surgical products and IVD diagnostic products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301584":1.5},"content_text":"证券之星消息，建发致新(301584)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好：作为贵公司的投资者，请问贵公司的神经血管介入市场在国内外的市场份额是多少？？谢谢！！建发致新回复：尊敬的投资者，您好！公司具体经营数据敬请关注公司在指定信息披露媒体披露的定期报告。公司持续推进血管介入、外科产品及IVD诊断产品等分销与直销业务的稳定发展，致力于巩固并提升市场份额。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640133385","isCrawlerRequest":true}